Empagliflozin (BI 10773) in Type Two Diabetes (T2D) Patients, Open Label Extension
Completed
Boehringer Ingelheim
Phase 2
2009-03-01
The objective of the current study is to investigate the safety and efficacy of BI 10773 in 2
different doses compared to Metformin or to Sitagliptin given for 78 weeks in different
modalities of treatment in patients with type 2 diabetes mellitus.
4 Weeks Treatment With Empagliflozin (BI 10773) in Japanese Type 2 Diabetic Patients (T2DM)
Completed
Boehringer Ingelheim
Phase 2
2009-04-01
The objective of this trial is to evaluate the pharmacodynamics, pharmacokinetics, safety,
and tolerability of once daily oral administration of BI 10773 administered for 28 days in
Japanese patients with T2DM.
Double Blind Placebo Study of JARDIANCE® (Empagliflozin) in Prehypertensives Type II Diabetics
Unknown status
Aristotle University Of Thessaloniki
Phase 4
2016-01-01
Objectives:
Primary
1. Primary prevention of new onset of hypertension
Secondary
1. Reduction of 24h BP in type II diabetics with prehypertension
2. Reduction of non dipping status, day and nighttime BP, morning BP surge in subjects
receiving EMPAGLIFLOZIN
3. Reduction in the total cardiovascular risk
4. 3 years morbidity and mortality rates
5. Arterial de-stiffening, reduction in central aortic blood pressure in subjects receiving
EMPAGLIFLOZIN
Pharmacokinetics of Empagliflozin (BI 10773) in Patients With Impaired Liver Function
Completed
Boehringer Ingelheim
Phase 1
2010-07-01
The main objective of this study is to assess the effect of mild, moderate and severe hepatic
impairment on the pharmacokinetics, safety and tolerability of BI 10773 following oral
administration of BI 10773 as a single dose.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
